Multiple cell and 3D systems are available to meet your specific needs:
2D genetically engineered skin cell models
SkinAxis provides intact and genetically engineered primary human skin models including epidermal keratinocytes, melanocytes, and dermal fibroblasts. Each cell type has been engineered to carry a stable transgene that allows the expression of the reporter upon activation of specific pathways. For testing of active ingredients, we follow the cellular response and reporter gene in cell-specific culture medium.
Advanced 3D skin models
SkinAxis established a wide range of in vitro 3D skin models. We provide 3D models developed using different types of skin cells. SkinAxis’ novel approach is based on the co-culture of multiple human primary skin cells in three-dimensional (3D) systems in physiologically relevant conditions in which skin’s native biology can be reconstituted and analyzed. We establish air-liquid interface in 3D models to generate stratification and differentiation of skin cells.
These models can be used to identify and validate active ingredients or final products.
QuantiSig® skin technology
SkinAxis has developed the Quantitative Signaling (QuantiSig®) technology that allows the analysis of the activation of different pathways representative of specific biological responses of the skin in a reproducible, highly sensitive, and measurable fashion. QuantiSig® is a cell engineering technology that can be applied both in 2D cell cultures as well as in the reconstitution of 3-dimensional skin models without interfering with the normal physiological responses of the cells.
3D skin models for detection of UV damage
SkinAxis generates 3D skin models for the highly sensitive detection of UV damage using genetically engineered skin cells. Each cell type is engineered to allow the expression a reporter gene upon activation of the DNA damage response pathway. As UV irradiation causes DNA damage, these cells are particularly suitable to assess the effects of UV on skin in a quantifiable manner. Engineered cells are able to reconstitute the normal architecture of skin tissue after establishing air-liquid interface and cultivation in differentiation media. Novel 3D skin models allow rapid and quantitative assessment of the effects of UVA and UVB irradiation.
3D skin models for anti-melanoma drug screening
SkinAxis provides multicellular 3D skin equivalent models that support the growth and progression of melanoma in a physiologically relevant tumor microenvironment. These models could be custom modified to provide testing platforms for specific inhibitors of melanoma growth including BRAF-inhibitors. These models will significantly impact the efficiency of preclinical studies by reducing the attrition rate of molecules under investigation.
Human macrophages differentiated from Peripheral Blood Mononuclear Cells (PBMC)-derived monocytes cultured for 10-13 days in the SkinAxis proprietary medium. Cultures are started only from monocyte preparation of the highest purity.
Oral mucosa equivalent
SkinAxis oral mucosa equivalent contains multiple layers of non-differentiated cells that could be induced to differentiate and form a multistrata, polarized, stratified epithelial layer with superficial keratinization. These models can be used for drug toxicity testing and investigation of therapeutic mechanisms.
SkinAxis is a biotechnology company that provides multicellular skin equivalent systems that reproduce the physiological properties of human skin tissues.
These models represent the response of human skin to drug and active ingredient treatment more accurately than animal models.
SkinAxis multicellular three-dimensional tissues can be customized using cell types engineered to specifically express gene reporter systems. These advanced models allow the faster, more sensitive, and more accurate assessment of the preclinical activity profile of drugs and active compounds.
All products by SkinAxis are made in the United States of America.
We seek to provide and develop solutions for cosmetic, biotechnology, pharmaceutical, chemical and diagnostics companies and academic laboratories interested in active ingredient testing and drug discovery.